Why AbbVie Stock Jumped Today
Shares of AbbVie (NYSE: ABBV) climbed on Monday after the pharmaceutical giant struck a deal to acquire clinical-stage biotech Apogee Therapeutics (NASDAQ: APGE) for $10.9 billion.
Image source: The Motley Fool.
Under the terms of the deal, AbbVie would purchase Apogee for $135.11 per share in cash. That's a 49% premium over the stock's closing price on Thursday, the last trading day before the deal's announcement.
Source Fool.com
AbbVie Inc. Stock
€218.10
1.020%
With 45 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 230 € there is a slightly positive potential of 5.46% for AbbVie Inc. compared to the current price of 218.1 €.


